###begin article-title 0
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
PTPRC (CD45) is not associated with multiple sclerosis in a large cohort of German patients
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 148 153 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 675 680 671 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 727 735 <span type="species:ncbi:9606">patients</span>
Since contradictory results have been reported, we reanalysed the 77C-->G transition in exon 4 of the protein-tyrosine phosphatase receptor-type C (PTPRC also known as CD45) in a large cohort of German MS patients and controls. Different isoforms of the protein are expressed, depending on alternative splicing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC) (CD45RO, exons 4-6 spliced out). The 77C-->G transition does not change the amino acid sequence, but it is probably part of a motif necessary for splicing leading to the isoform CD45RA. The expression of CD45RA is increased in 77C/G heterozygous individuals. The aim of the study was to clarify the importance of the PTPRC 77C-->G transition in our German cohort of MS patients.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
PCR products of exon 4 were digested using endonuclease MspI. The resulting restriction fragments of the wildtype C allele are 198 and 62 bp in length. In the G allele an additional restriction site is present yielding fragments of 114 and 84 bp.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 404 415 402 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15</italic>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 175 182 <span type="species:ncbi:9606">patient</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
The G allele was identified in 10 of the 347 controls (1.4%) and in 7 of 454 MS patients (0.8%; Table 1). No homozygous individuals were found either in the control or in the patient group. Genetic association between the PTPRC 77C-->G transition and MS susceptibility was excluded in the MS cohort. In addition, subgrouping patients according to differences in the clinical course of MS or according to HLA-DRB1*15 status did not yield significant differences.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 40 45 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 209 217 <span type="species:ncbi:9606">patients</span>
The 77C-->G transition in exon 4 of the PTPRC gene may contribute to MS susceptibility only in very few families, if at all, but it is not relevant for the majority of MS cases, including virtually all German patients.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 492 497 490 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 519 520 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 523 528 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 690 691 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1277 1278 1273 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system by demyelination. Both environmental and genetic components contribute to the development of MS. An efficient strategy to elucidate the genetic background of MS is to analyse single nucleotide polymorphisms (SNPs) in respective candidate genes. Since contradictory results have been reported recently [1-3], we analysed the 77C-->G transition in exon 4 of the protein-tyrosine phosphatase receptor-type C (PTPRC also known as CD45) [4]. PTPRC is localized on chromosome 1q31-q32 and consists of 35 exons. The gene encodes a 180-220 kDa glycoprotein expressed on leukocytes and hematopoietic progenitors [4]. This receptor is involved in T and B cell activation and in signal transduction by regulating protein-tyrosine kinases. Because of this involvement in immunological reactions, the gene is a candidate for MS predisposition. The protein exists in multiple isoforms, depending on alternative splicing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC) (CD45RO, exon 4-6 spliced out). The 77C-->G transition does not change the amino acid sequence, but it is probably part of a motif necessary for splicing of CD45RA. The expression of CD45RA is increased in 77C/G heterozygous individuals [1].
###end p 10
###begin p 11
###xml 46 52 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC.</italic>
Allele frequency of the 77C-->G transition in PTPRC. Homozygosity was not observed.
###end p 11
###begin p 12
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
* p = 0.2. RRMS = relapsing remitting course of MS; SPMS = secondary progressive course of MS; PPMS = primary progressive course of MS
###end p 12
###begin title 13
Methods
###end title 13
###begin p 14
###xml 924 925 910 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
###xml 845 853 <span type="species:ncbi:9606">patients</span>
Peripheral blood samples from more than 400 healthy blood donors were obtained with their informed consent, and provided by the department of transplantation and immunology of the University Hospital Eppendorf (Hamburg, Germany). The mean age of the healthy donors was 39.3 +/- 11.47 years. The male/female ratio was 1.4 +/- 0.5. More than 800 unrelated MS patients attending the Department of Neurology, University clinics of Bochum and Gottingen (Germany) participated in this study. The male/female ratio was 1.7 +/- 0.47, the mean age at MS onset was 29.9 +/- 9.63 years. 55.3% of all clinically diagnosed MS patients exhibited a relapsing/remitting course of MS (RRMS), 25.8% developed secondary progressive MS (SPMS) and 18.9% were characterized by primary progressive MS (PPMS). The mean EDSS (expanded disability status scale) of all MS patients was 4.2 +/- 2.31, of PPMS 5.8 +/- 1.91 and of RRMS+SPMS 3.9 +/- 2.25 [5].
###end p 14
###begin p 15
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 153 158 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 621 624 589 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 929 930 897 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Polymerase chain reaction (PCR) of exon 4 of PTPRC was carried out in a final volume of 12.5 mul with 50 ng of DNA, 200 muM dNTP, 1 U Taq Polymerase and PTPRC exon 4 specific primers (forward, 5'-ATTTATTTTGTCCTTCTCCCA-3' and reverse, 5'-GTTAACAACTTTTGTGTGCCAAC-3'). PCR cycling started with initial denaturation for 5 minutes at 94degreesC. The annealing temperature of the first cycle was 61degreesC, second cycle 58degreesC and remaining 26 cycles 55degreesC. The annealing time was 1 minute. Extension was performed at 72degreesC for 1 minute (final extension 5 minutes). PCR products were digested using endonuclease MspI according to the manufacturer's recommendation. Digested DNA was electrophoresed on 1.5% agarose gels. The restriction fragments of the wildtype C allele were 198 and 62 bp in length. The G allele harbors an additional restriction site so that the 198 bp fragment is digested into 114 and 84 bp (Figure 1).
###end p 15
###begin p 16
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
Restriction fragment length polymorphism (RFLP) analysis of PTPRC exon 4 77C-->G; M=pUC19 DNA marker (501, 489, 404, 331, 242, 190, 147, 111, 110, 67 bp)
###end p 16
###begin title 17
Results
###end title 17
###begin p 18
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 419 430 417 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15</italic>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 170 177 <span type="species:ncbi:9606">patient</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
The rare G allele was present in 10 of the 347 controls (1.4%) and in 7 of 454 MS patients (0.8%; Table 1). There were no homozygous individuals either in the control or patient groups. Genetic association between the PTPRC 77C-->G transition and MS susceptibility was excluded in the MS cohort. In addition, subgrouping patients according to differences in the clinical course of MS (RRMS, SPMS, PPMS) or according to HLA-DRB1*15 status did not yield significant differences.
###end p 18
###begin title 19
Discussion
###end title 19
###begin p 20
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 56 57 56 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
This result contradicts the findings of Jacobsen et al.[1] who demonstrated an association of the mutation with MS in 3 families. Barcellos et al.[2] and Vorechovsky et al. [3] excluded MS association as well. However, as yet unknown polymorphisms in the PTPRC gene may contribute to MS susceptibility.
###end p 20
###begin title 21
Conclusions
###end title 21
###begin p 22
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
In conclusion, the PTPRC exon 4 77C-->G transition seems to contribute to MS susceptibility only in a few families, if at all, but it is not relevant for the majority of MS cases, also not in virtually all German patients.
###end p 22
###begin title 23
Competing interests
###end title 23
###begin p 24
None declared.
###end p 24
###begin title 25
Authors' contributions
###end title 25
###begin p 26
###xml 70 78 <span type="species:ncbi:9606">patients</span>
BM carried out the molecular analyses, ES, MH, and SS examined the MS patients, and JE participated in the study design and the coordination.
###end p 26
###begin p 27
All authors have read and approved the final manuscript.
###end p 27
###begin title 28
Pre-publication history
###end title 28
###begin p 29
The pre-publication history for this paper can be accessed here:
###end p 29
###begin p 30

###end p 30
###begin title 31
Acknowledgements
###end title 31
###begin p 32
###xml 30 38 <span type="species:ncbi:9606">patients</span>
We would like to thank the MS patients for participating in this study, Susann Schiwy, Gudrun Rodepeter and Margret Schumacher for excellent technical assistance and Professor David Ballantyne for his expert corrections of the scientific English. This work was supported by BMBF (01GG9841).
###end p 32
###begin article-title 33
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
A point mutation in PTPRC is associated with the development of multiple sclerosis.
###end article-title 33
###begin article-title 34
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients.
###end article-title 34
###begin article-title 35
###xml 16 21 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
Does 77C-->G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus?
###end article-title 35
###begin article-title 36
###xml 24 29 <span type="species:ncbi:9606">human</span>
A point mutation in the human CD45 gene associated with defective splicing of exon A.
###end article-title 36
###begin article-title 37
Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations.
###end article-title 37

